Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies

Supplements And Featured PublicationsBTK Inhibitors in B-Cell Lymphomas
Volume 1
Issue 1

Shuo Ma, MD, PhD, highlights ongoing ​research with BTK inhibitor​s in B​-cell malignancies. 

Shuo Ma, MD, PhD, associate professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, ​Northwestern University Feinberg School of Medicine, highlights ongoing ​research with BTK inhibitor​s in B​-cell malignancies. 

Currently, the BTK inhibitors ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa) ​have indications in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia, ​says Ma. Ibrutinib is a first-generation BTK inhibitor, whereas acalabrutinib and zanubrutinib are second-generation ​BTK inhibitors.

Ibrutinib​ inhibits the BTK enzyme, which is a critical component of B​-cell biology, survival, and proliferation. However, ibrutinib affects other tyrosine kinases, such as EGFR​, Ma explains.

As a result, patients may experience off-target toxicities with ibrutinib, ​adds Ma.

​Although head-to-head clinical trials are needed, acalabrutinib and zanubrutinib may elicit less toxicity compared with ibrutinib as the agents are more selective, Ma concludes.

Related Videos
Wesley J. Talcott, MD, MBA
Tiago Biachi, MD, PhD
Kevin Kayvan Zarrabi, MD, MS, FACP
Arutha Kulasinghe, PhD
Andrea Billè, MD
Tian Zhang, MD, MHS
Anand Narayan, MD, PhD
J. Randolph (Randy) Hecht, MD
Qian (Janie) Qin, MD
Related Content